MedTrace Logo

Indole-3-Carbinol in Preventing Cancer in Healthy Participants

NCT00100958 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2008-07-24

No results posted yet for this study

Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of indole-3-carbinol may prevent cancer.

PURPOSE: This randomized phase I trial is studying the side effects and best dose of indole-3-carbinol and to see how well it works compared to placebo in preventing cancer in healthy participants.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

indole-3-carbinol

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Kansas

    lead OTHER

Principal Investigators

  • Gregory Reed, PhD · University of Kansas

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00100958 on ClinicalTrials.gov